TP53 and lung carcinoma: According to a pooled analysis of data from the International Adjuvant Lung Cancer Trial and three other randomized trials, the LACE‐Bio Collaborative Group reported that TP53 mutations had no significant predictive value on the outcome of platinum‐based adjuvant chemotherapy.